Incidental Adrenal Nodule on Staging CT: When to Work Up
A 58-year-old woman with newly diagnosed breast cancer undergoes a staging CT of the chest, abdomen, and pelvis with contrast. A 2.1 cm left adrenal nodule is identified. It is homogeneous, has smooth margins, and measures approximately 15 Hounsfield units on the portal venous phase. There is no prior imaging for comparison. She is asymptomatic and has no history of hypertension, palpitations, or weight change. Her oncologist asks whether the adrenal finding changes staging and whether it needs further workup before treatment planning.
1. How would you characterize this adrenal nodule, and what is the appropriate next step?
Read the worked answer
This is an incidental adrenal nodule in a patient with known malignancy, so the differential includes metastasis, adenoma, and (less likely) other entities.
Characterization:
- Size 2.1 cm, homogeneous, smooth margins - morphologically benign features, but size alone does not exclude malignancy.
- Attenuation ~15 HU on portal venous phase is indeterminate on a single venous phase; a dedicated unenhanced CT is needed. A homogeneous nodule with unenhanced attenuation ≤10 HU is diagnostic of a lipid-rich adenoma and requires no further workup.
- If unenhanced attenuation is >10 HU, perform chemical-shift MRI or a contrast washout CT (absolute washout >60% or relative washout >40% supports adenoma).
Next step: obtain unenhanced CT (or chemical-shift MRI) to characterize the nodule. If it proves to be an adenoma, no further action. If indeterminate or suspicious, consider PET/CT or biopsy in the context of the oncologic plan.
2. The oncologist asks whether this finding changes staging. Explain how you would determine that and what else you would review.
Read the worked answer
Staging impact depends on whether the nodule represents a metastasis.
- For breast cancer, an isolated adrenal metastasis would generally constitute stage IV (M1) disease and substantially change management (systemic therapy rather than curative-intent local therapy).
- Therefore the nodule must be characterized before assigning M1 status. A lipid-rich adenoma (≤10 HU unenhanced) would be benign and would not change stage.
Additional review:
- Re-examine the chest and abdomen for other sites of disease (liver, bone, lung, contralateral adrenal) - a solitary indeterminate adrenal nodule in the absence of other metastases is more likely benign.
- Compare with any prior imaging if it can be retrieved.
- Consider FDG-PET/CT, which is useful for characterizing indeterminate adrenal nodules and for detecting occult metastases; an adenoma typically shows uptake equal to or less than liver, whereas a metastasis is usually FDG-avid.
Document the recommendation and coordinate with oncology so treatment planning is not delayed unnecessarily.